A Randomized Phase I/II Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Trial Profile

A Randomized Phase I/II Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs CD40L GVAX (Primary) ; Nivolumab
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Mar 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jun 2018.
    • 26 Feb 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.
    • 01 Dec 2017 Planned initiation date changed from 1 Jan 2018 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top